Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield (Q80008483)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

2

H M Lokhorst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

4

B van der Holt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

I Breitkreutz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M S Raab

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

F W Cremer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

D Herrmann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

A Glasmacher

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

I G H Schmidt-Wolf

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

I W Blau

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

H Martin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

H Salwender

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

A Haenel

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

P Sonneveld

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

H Goldschmidt

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

22 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

1294-1299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17377586%20AND%20SRC:MED&resulttype=core&format=json

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Therapeutic application of thalidomide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404661

7 January 2021